Last week, DaVita (DVA) released its Q3/19 results (call transcript) and enjoyed a rare rally, presumably mostly because of short covering. It has been a battleground stock for some time and expectations were low.
With its Q3 results DaVita managed to outperform market expectations, as it managed to squeeze more gains out of the calcimimetics issue, so that revenue/treatment increased by $1, while costs/treatment were down $10 YoY. Close to $10 of the net benefit was from calcimimetics, which generated a stunning $74m of operating profits in Q3 and for the